Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Q2 2025 earnings

Reported August 13, 2025 · Before market open

Revenue$1.3M
EPS-$1.85Beat by $1.07
EPS estimate-$2.92

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$1.9M
EPS estimate-$2.50

Financials

Q2 2025

Income statement

See full
Revenue$1.3M+1,200%
Operating income-$27.4M+83.0%
Net income-$28.7M-102%
EPS (diluted)-$1.85-101%

Balance sheet

See full
Cash & equivalents$186.6M-17.8%
Total debt$106.8M+4,819%
Total equity$68.6M-68.7%
Total assets$212.1M-17.9%

Cash flow

See full
Operating cash flow-$30.0M+47.8%
Free cash flow-$30.0M+48.9%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$213.66M+4.2%
Enterprise value$133.89M+784%
P/S152.6×+41.9×

Profitability

See full
Operating margin-11,929.6%-3,413pp
Net margin-8,273.5%-96,450pp
FCF margin-10,009.5%-1,811pp

Returns & leverage

See full
Return on equity-80.5%—
Debt / equity1.6×+1.5×
Current ratio5×-1.2×

Segments

By segment

See full
Reportable Segment$1.3M—

By product

See full
License fee revenue$1.3M—

FAQ

When did Inhibrx Biosciences, Inc. report Q2 2025 earnings?
Inhibrx Biosciences, Inc. (INBX) reported Q2 2025 earnings on August 13, 2025 before market open.
What were Inhibrx Biosciences, Inc.'s Q2 2025 revenue and EPS?
Inhibrx Biosciences, Inc. reported revenue of $1.3M and eps of $-1.85 for Q2 2025.
Did Inhibrx Biosciences, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-2.92 by $1.07.
How did Inhibrx Biosciences, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1200.0% from $100.0K a year earlier.
Where can I find Inhibrx Biosciences, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0002007919-25-000083) and the 10-Q periodic report (0002007919-25-000081) directly on SEC EDGAR. The filing index links above go to sec.gov.